Diversified Healthcare Trust (DHC) Q2 2025 Earnings Call Transcript

Diversified Healthcare Trust (DHC) reported strong Q2 2025 results, exceeding analyst expectations, with FFO increasing 172% year-over-year to $0.08 per share and same-property SHOP Net Operating Income (NOI) rising 18.5%. Revenue grew 3% to $382.7 million, and Adjusted EBITDAre increased 7% to $73.6 million. The company significantly advanced its deleveraging strategy, paying off 2025 notes, securing $343 million in new financings, and establishing a $150 million credit facility. DHC is actively pursuing $280 million in asset dispositions, primarily in Q3/Q4, to address its $641 million January 2026 bond maturity and reduce its net debt to adjusted EBITDAre from 8.7x towards a 6.5-7.5x target. Reflecting this progress, DHC raised its 2025 SHOP NOI guidance to $132 million-$142 million and reduced CapEx guidance to $140 million-$160 million, signaling confidence in its operational improvements and balance sheet strengthening.

Analysis

Diversified Healthcare Trust (DHC) reported strong second-quarter 2025 results, demonstrating significant progress in its operational turnaround and balance sheet deleveraging strategy. Funds from Operations (FFO) increased 172% year-over-year to $0.08 per share, while revenue grew 3% to $382.7 million, meeting analyst expectations. The primary driver of this performance was the Senior Housing Operating Portfolio (SHOP), where same-property Net Operating Income (NOI) surged 18.5% year-over-year, propelled by a 160 basis point occupancy gain to 80.6% and a 5.4% increase in average monthly rates. This operational momentum prompted management to raise its full-year 2025 SHOP NOI guidance by $10 million at the midpoint to a range of $132 million to $142 million. Concurrently, DHC is executing a clear deleveraging plan to address its $641 million bond maturity due in January 2026. The company has already paid off its 2025 notes, secured $343 million in new fixed-rate financing at a favorable 6.5% weighted average interest rate, and has a disposition pipeline of $280 million under agreement or LOI. Successful execution of these asset sales and a planned $300-$350 million financing in Q3 is expected to reduce net debt to adjusted EBITDAre from 8.7x toward the company's target of 6.5x-7.5x, significantly strengthening its financial profile.

Key Decisions for Investors

• Given the robust 18.5% growth in same-property SHOP NOI and increased full-year guidance, investors should view the operational turnaround as having significant momentum, warranting close attention to occupancy trends as they build toward the 82.5% year-end target.
• The primary catalyst for share performance is the successful execution of the deleveraging plan; therefore, monitor the closing of the $280 million in asset sales and the announcement of the final $300-$350 million financing tranche expected in Q3, as any delays could reintroduce balance sheet risk.
• With management explicitly stating a belief that the shares are undervalued and presenting a clear path to reducing leverage, investors may consider the current valuation an attractive entry point, contingent on the successful retirement of the January 2026 notes.
• Note that recurring capital expenditures are expected to normalize around $3,500 per unit in the SHOP portfolio from 2026 onwards, which, combined with the disposition of non-core assets, should materially improve free cash flow generation beyond the current turnaround phase.